SCHEMBL3568466

SCHEMBL3568466

NC(=O)N(c1ccc(Cl)cc1)C(C(=O)O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 6/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
MDM2 Q00987 1/20 0.40
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX5 P09917 1/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
S1PR4 O95977 1/20 0.37
S1PR3 Q99500 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5801209 0.91 TRPM8 (0.47) TRPM8CES2CES1MDM2GAA
SCHEMBL7560686 0.89 ALOX5 (0.44) TRPM8ALOX5ALDH1A1MAPTSMN1; SMN2
SCHEMBL5151874 0.84 LMNA (0.46) TRPM8CES2CES1ALOX5ALDH1A1
SCHEMBL3563022 0.84 MDM2 (0.41) CES2CES1MDM2KDM4EALDH1A1
SCHEMBL3557436 0.81 PPARG (0.38) TRPM8CES2CES1MDM2ALDH1A1
SCHEMBL3563412 0.81 PPARA (0.38) CES2CES1MDM2GAAALDH1A1
SCHEMBL3569300 0.81 CNR2 (0.41) CES2CES1MDM2GAAALDH1A1
SCHEMBL3564244 0.81 CES2 (0.36) CES2CES1MDM2GAAALDH1A1
SCHEMBL3566188 0.79 ATM (0.45) KDM4EALDH1A1NPC1MAPTSMN1; SMN2
SCHEMBL5802781 0.79 TRPM8 (0.45) TRPM8CES2CES1MDM2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 TRPM8 3464/4885CES2 628/4885CES1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.